A copy of this work was available on the public web and has been preserved in the Wayback Machine. The capture dates from 2018; you can also visit the original URL.
The file type is application/pdf
.
Do Imaging Biomarkers Relate to Outcome in Patients Treated with VEGF Inhibitors?
2012
Clinical Cancer Research
The management of solid tumors has been transformed by the advent of VEGF pathway inhibitors. Early clinical evaluation of these drugs has used pharmacodynamic biomarkers derived from advanced imaging such as dynamic MRI, computed tomography (CT), and ultrasound to establish proof of principle. We have reviewed published studies that used these imaging techniques to determine whether the same biomarkers relate to survival in renal, hepatocellular, and brain tumors in patients treated with VEGF
doi:10.1158/1078-0432.ccr-12-1501
pmid:23092875
fatcat:fkgpfhw6knes5fda6akid4ktza